cp-724714
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2003 (NCT00055926)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1- Mol. weight
- 469.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL483321 ↗
Also known as
- 2-methoxy-n-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide
- cp724714
- cp 724714
- cp 724,714
- cp-724714
- cp-724714
- cp-724714
- cp-724714
- cp-724,714
- cp-724,714
- cp-724,714
- cp724,714
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00102895 | Phase 2 | Apr 1, 2005 | Pfizer |
| NCT00055926 | Phase 1 | Jan 1, 2003 | National Cancer Institute (NCI), University of California, Los Angeles |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2003 |
| Pfizer | For profit | 1 | 1 | 1 | 2005 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2003 |
3 organizations
Page 1 / 1